Skip to main content

General Dermatology Content

What is the primary reason for skin of color (SOC) being more likely to develop pigmentary sequelae?
FDA Alerts
The FDA announced that ligelizumab has received the Breakthrough Therapy designation for the treatment of chronic spontaneous urticaria for patients who have had an inadequate response to H1-antihistamines.
Previous studies have inconclusive findings regarding the association of bullous pemphigoid and solid malignancies. A recent study published in The Journal of Dermatology found that patients with bullous pemphigoid do not have an overall increased risk of developing a solid malignancy.
Combination treatment with a home-based handheld narrowband UV-B (NB-UVB) and a topical corticosteroid (TCS) may be a more effective option for treatment of localized vitiligo than TCS alone. The results of the study comparing the two therapies were published in British Journal of Dermatology.
A majority of patients with a symptomatic keloid treated with a 1064-nm Nd:YAG laser exclusively saw a total resolution in pain after treatment. The study results were published in Lasers in Surgery and Medicine.
Cover Story
Lauren Mateja, Managing Editor
As a largely misunderstood and misdiagnosed disease, hidradenitis suppurativa is beginning to come to the forefront of dermatologic research.
Angela Ballard, RN
Fine-tune your understanding of hyperhidrosis and honor Hyperhidrosis Awareness Month throughout November.
In this podcast, Peter Lio, MD, discusses how atopic dermatitis lesion location impacts patients' quality of life, and why it is important for dermatologists to discuss quality of life concerns with patients.
Findings from a recent study found risankizumab improved both moderate to severe psoriasis symptoms and patients’ quality of life.
Back to Top